Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia.

نویسندگان

  • Daniel C Link
  • Ghada Kunter
  • Yumi Kasai
  • Yu Zhao
  • Tracie Miner
  • Michael D McLellan
  • Rhonda E Ries
  • Deepak Kapur
  • Rakesh Nagarajan
  • David C Dale
  • Audrey Anna Bolyard
  • Laurence A Boxer
  • Karl Welte
  • Cornelia Zeidler
  • Jean Donadieu
  • Christine Bellanné-Chantelot
  • James W Vardiman
  • Michael A Caligiuri
  • Clara D Bloomfield
  • John F DiPersio
  • Michael H Tomasson
  • Timothy A Graubert
  • Peter Westervelt
  • Mark Watson
  • William Shannon
  • Jack Baty
  • Elaine R Mardis
  • Richard K Wilson
  • Timothy J Ley
چکیده

Severe congenital neutropenia (SCN) is an inborn disorder of granulopoiesis. Like most other bone marrow failure syndromes, it is associated with a marked propensity to transform into a myelodysplastic syndrome (MDS) or acute leukemia, with a cumulative rate of transformation to MDS/leukemia that exceeds 20%. The genetic (and/or epigenetic) changes that contribute to malignant transformation in SCN are largely unknown. In this study, we performed mutational profiling of 14 genes previously implicated in leukemogenesis using 14 MDS/leukemia samples from patients with SCN. We used high-throughput exon-based resequencing of whole-genome-amplified genomic DNA with a semiautomated method to detect mutations. The sensitivity and specificity of the sequencing pipeline was validated by determining the frequency of mutations in these 14 genes using 188 de novo AML samples. As expected, mutations of tyrosine kinase genes (FLT3, KIT, and JAK2) were common in de novo AML, with a cumulative frequency of 30%. In contrast, no mutations in these genes were detected in the SCN samples; instead, mutations of CSF3R, encoding the G-CSF receptor, were common. These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

The Association of FLT3-ITD Gene Mutation with Bone Marrow Blast Cell Count, CD34, Cyclin D1, Bcl-xL and hENT1 Expression in Acute Myeloid Leukemia Patients

Background & Objective:  FLT3-ITD has been recently used as a molecular prognostic marker for risk classification in acute myeloid leukemia (AML) therapy. In this study we aimed to investigate the association of FLT3-ITD gene mutation with bone marrow blast cell count, CD34 ex...

متن کامل

The Difference in Initial Leukocyte Count, Bone Marrow Blast Cell Count and CD 34 Expression in Patients with Acute Myeloid Leukemia with and without NPM1 gene Mutation

Background: Mutation in NPM1 gene has been reported to be the most common genetic mutation in de novo acute myeloid leukemia (AML). AML with NPM1 gene mutation usually presents with higher initial leukocyte and blast cell counts and negative CD34 expression. We aimed to investigate the difference of initial leukocyte counts, bone marrow blast cell counts and expression of CD34 among patients wi...

متن کامل

Sequential gain of mutations in severe congenital neutropenia progressing to acute myeloid leukemia.

Severe congenital neutropenia (SCN) is a BM failure syndrome with a high risk of progression to acute myeloid leukemia (AML). The underlying genetic changes involved in SCN evolution to AML are largely unknown. We obtained serial hematopoietic samples from an SCN patient who developed AML 17 years after the initiation of G-CSF treatment. Next- generation sequencing was performed to identify mut...

متن کامل

Frequency of DNMT3A Mutations in Patients with Acute Leukemia in Mashhad

Background and Aims: DNA methyltransferase3A (DNMT3A) is necessary for the adjustment of gene expression, and the mutations in the DNMT3A gene are reported in a variety of leukemia cases. DNMT3A mutations are during cancer progression and cause poor prognosis in many leukemias. Thus, this gene can be a target for new treatments. This study aimed to examine the distribution of DNMT3A mutations i...

متن کامل

Evaluation of ATG7 and Light Chain 3 (LC3) Autophagy Genes Expression in Newly Diagnosed AML Patients

Evaluation of ATG7 and LC3 Autophagy Genes Expression in Newly Diagnosed AML patients Background and aim: Autophagy, known as cell death type II, is a housekeeping pathway that currently has been worked on in matters of tumorigenesis and leukemogenesis. Therefore, in this study expression levels of ATG7 and LC3 as two key genes are targeted in AML patients. Material and method: This...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Blood

دوره 110 5  شماره 

صفحات  -

تاریخ انتشار 2007